{
  "docId": "019de073-8079-71bb-b12b-cbebf2163a3a",
  "docSlug": "9b4d00e952721e20753466aee3e72db7",
  "documentTitle": "BenevolentAI | Investor Day Presentation Deck | 74 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 61,
  "pageCount": 74,
  "prevPage": 60,
  "nextPage": 62,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8079-71bb-b12b-cbebf2163a3a/61",
  "deckHref": "/decks/019de073-8079-71bb-b12b-cbebf2163a3a",
  "deckJsonHref": "/decks/019de073-8079-71bb-b12b-cbebf2163a3a.json",
  "deckAnchorHref": "/decks/019de073-8079-71bb-b12b-cbebf2163a3a#slide-61",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.47,
        "y": 0.275
      },
      "kind": "callout",
      "text": "An opportunity to differentiate on safety, efficacy and a precision medicine approaches",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10da6efd-1cc0-4b0f-8923-ba6a585c17ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.78,
        "y": 0.5
      },
      "kind": "list",
      "text": "S1P1 agonists are associated with immunosuppression and anaemia. JAK inhibitors carry a black box health warning",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0312ef83-3fdb-4fb7-8e67-9c90baf2ed7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.06,
        "y": 0.265
      },
      "kind": "list",
      "text": "Phosphodiesterase 10 (PDE10) was identified by our TargetID platform as an entirely novel target for the treatment of UC/IBD. Using our Molecular Design expertise we optimally designed a best in class peripherally restricted PDE10 inhibitor: BEN-8744. BEN-8744 is expected to provide an efficacious disease modifying oral treatment for UC/IBD. BEN-8744 will target Moderate and Severe UC/IBD patients, meeting the unmet need left by existing therapies including: Patients refractory to anti-TNFs or other biologics. Improved safety and tolerability profile compared to competitors. A Precision Medicine approach to target key responder patient cohorts, avoiding the safety risks associated with ineffective therapies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ab6609c-6993-438b-a310-abd871c717df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.47,
        "y": 0.415
      },
      "kind": "table",
      "text": "Drug, Company, MoA. Zeposia (Ozanimod), BMS, S1P1 receptor agonist. Etrasimod, Arena, S1P1 receptor agonist. Jyseleca (Filgotinib), Galapagos & Gilead, JAK1 inhibitor. Rinvoq (Upadacitinib), Abbvie, JAK1 inhibitor. TD-1473, Theravance & Janssen, Pan-JAK inhibitor (gut-selective).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d16af65-ef3f-4582-b498-3e24d3bdec4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BEN-8744 - Best-in-class, oral, peripherally restricted potent and selective drug for the treatment of Moderate-Severe UC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb0cdd4a-2a76-47ab-88d7-ada782ef10c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 74,
      "from": 8,
      "beatId": "e075ee7a-56af-49ed-87dd-38efd7ca183a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The Benevolent Platform™: a versatile, scalable and proven AI-enabled R&D engine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}